166 related articles for article (PubMed ID: 38196889)
1. Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics.
Jayne DRW; Terrier B; Hellmich B; Khoury P; Baylis L; Bentley JH; Steinfeld J; Yancey SW; Kwon N; Wechsler ME; Akuthota P
ERJ Open Res; 2024 Jan; 10(1):. PubMed ID: 38196889
[TBL] [Abstract][Full Text] [Related]
2. Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype.
Terrier B; Jayne DRW; Hellmich B; Bentley JH; Steinfeld J; Yancey SW; Kwon N; Akuthota P; Khoury P; Baylis L; Wechsler ME;
ACR Open Rheumatol; 2023 Jul; 5(7):354-363. PubMed ID: 37312233
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
Steinfeld J; Bradford ES; Brown J; Mallett S; Yancey SW; Akuthota P; Cid MC; Gleich GJ; Jayne D; Khoury P; Langford CA; Merkel PA; Moosig F; Specks U; Weller PF; Wechsler ME
J Allergy Clin Immunol; 2019 Jun; 143(6):2170-2177. PubMed ID: 30578883
[TBL] [Abstract][Full Text] [Related]
4. Anti-cytokine targeted therapies for ANCA-associated vasculitis.
Bala MM; Malecka-Massalska TJ; Koperny M; Zajac JF; Jarczewski JD; Szczeklik W
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD008333. PubMed ID: 32990324
[TBL] [Abstract][Full Text] [Related]
5. Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis (EGPA) in Japan: 48-week interim analysis of the MARS study.
Ishii T; Kunishige H; Kobayashi T; Hayashi E; Komatsubara M; Ishii T; Alfonso-Cristancho R; Tamaoki J; Howarth P
Mod Rheumatol; 2023 Dec; ():. PubMed ID: 38100679
[TBL] [Abstract][Full Text] [Related]
6. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME; Akuthota P; Jayne D; Khoury P; Klion A; Langford CA; Merkel PA; Moosig F; Specks U; Cid MC; Luqmani R; Brown J; Mallett S; Philipson R; Yancey SW; Steinfeld J; Weller PF; Gleich GJ;
N Engl J Med; 2017 May; 376(20):1921-1932. PubMed ID: 28514601
[TBL] [Abstract][Full Text] [Related]
7. Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis.
Vultaggio A; Nencini F; Bormioli S; Vivarelli E; Dies L; Rossi O; Parronchi P; Maggi E; Matucci A
Allergy Asthma Immunol Res; 2020 Sep; 12(5):885-893. PubMed ID: 32638567
[TBL] [Abstract][Full Text] [Related]
8. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME; Nair P; Terrier B; Walz B; Bourdin A; Jayne DRW; Jackson DJ; Roufosse F; Börjesson Sjö L; Fan Y; Jison M; McCrae C; Necander S; Shavit A; Walton C; Merkel PA;
N Engl J Med; 2024 Mar; 390(10):911-921. PubMed ID: 38393328
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
[TBL] [Abstract][Full Text] [Related]
10. Factors Affecting the Ability to Discontinue Oral Corticosteroid Use in Patients with EGPA Treated with Anti-Interleukin-5 Therapy.
Matsuno O
Int Arch Allergy Immunol; 2024; 185(2):116-123. PubMed ID: 37906985
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and Disease Burden of Patients With Eosinophilic Granulomatosis With Polyangiitis Initiating Mepolizumab in the United States.
Silver J; Deb A; Packnett E; McMorrow D; Morrow C; Bogart M
J Clin Rheumatol; 2023 Dec; 29(8):381-387. PubMed ID: 37779234
[TBL] [Abstract][Full Text] [Related]
12. Trends in prevalence, treatment use, and disease burden in patients with eosinophilic granulomatosis with polyangiitis in Japan: real-world database analysis.
Sada KE; Suzuki T; Joksaite S; Ju S; Logie J; Mu G; Hwee J; Kunishige H; Ishii T; Adlak A; Vadlamudi H; Alfonso-Cristancho R
Mod Rheumatol; 2023 Nov; ():. PubMed ID: 37930840
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of conventional immunosuppressants in relapsing or refractory eosinophilic granulomatosis with polyangiitis: evidence from a Canadian single-centre cohort.
Doubelt I; Pulenzas N; Carette S; Pagnoux C;
Clin Exp Rheumatol; 2020; 38 Suppl 124(2):171-175. PubMed ID: 32167871
[TBL] [Abstract][Full Text] [Related]
14. Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy.
Faverio P; Bonaiti G; Bini F; Vaghi A; Pesci A
Ther Clin Risk Manag; 2018; 14():2385-2396. PubMed ID: 30573961
[TBL] [Abstract][Full Text] [Related]
15. Early add-on administration of mepolizumab and intravenous immunoglobulin effective in treating eosinophilic granulomatosis with polyangiitis.
Ikeda T; Komatsu T; Yokoyama K; Takahashi K; Kawakami T
J Dermatol; 2021 Apr; 48(4):529-532. PubMed ID: 33305381
[TBL] [Abstract][Full Text] [Related]
16. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?
Vergles M; Matković Z; Lalić K; Trkanjec JT; Tudorić N
J Asthma; 2021 Dec; 58(12):1675-1679. PubMed ID: 32962455
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis.
Condreay LD; Parham LR; Qu XA; Steinfeld J; Wechsler ME; Raby BA; Yancey SW; Ghosh S
Rheumatol Int; 2020 Aug; 40(8):1301-1307. PubMed ID: 32009195
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Low-Dose Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Real-Life Experience.
Özdel Öztürk B; Yavuz Z; Aydın Ö; Mungan D; Sin BA; Demirel YS; Bavbek S
Int Arch Allergy Immunol; 2022; 183(12):1281-1290. PubMed ID: 36126640
[TBL] [Abstract][Full Text] [Related]
19. Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study.
Bettiol A; Urban ML; Dagna L; Cottin V; Franceschini F; Del Giacco S; Schiavon F; Neumann T; Lopalco G; Novikov P; Baldini C; Lombardi C; Berti A; Alberici F; Folci M; Negrini S; Sinico RA; Quartuccio L; Lunardi C; Parronchi P; Moosig F; Espígol-Frigolé G; Schroeder J; Kernder AL; Monti S; Silvagni E; Crimi C; Cinetto F; Fraticelli P; Roccatello D; Vacca A; Mohammad AJ; Hellmich B; Samson M; Bargagli E; Cohen Tervaert JW; Ribi C; Fiori D; Bello F; Fagni F; Moroni L; Ramirez GA; Nasser M; Marvisi C; Toniati P; Firinu D; Padoan R; Egan A; Seeliger B; Iannone F; Salvarani C; Jayne D; Prisco D; Vaglio A; Emmi G;
Arthritis Rheumatol; 2022 Feb; 74(2):295-306. PubMed ID: 34347947
[TBL] [Abstract][Full Text] [Related]
20. Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan.
Yamane T; Hashiramoto A
Arthritis Res Ther; 2023 Jun; 25(1):110. PubMed ID: 37365612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
